only with
Aurobindo Pharma Ltd.
Aurobindo Pharma
Aurobindo Pharma Ltd. live price is ₹ 0.00. Price change 0.00, 0.00 percent.
₹ 0.00
0.00 (0.00)%
Healthcare
Mid-cap - With a market cap of ₹823.31 Cr.
| EX-Date | Purpose |
|---|---|
| 31 05 2021 | Audited Results |
| 12 08 2021 | Interim Dividend & Quarterly Results |
| 08 11 2021 | Quarterly Results & Second Interim Dividend |
| 09 02 2022 | Third Interim Dividend & Quarterly Results |
| 30 05 2022 | Audited Results & Fourth Interim Dividend |
| 11 08 2022 | Quarterly Results |
| 12 11 2022 | Quarterly Results |
| 09 02 2023 | Quarterly Results & Interim Dividend |
| 27 05 2023 | Audited Results |
| 12 08 2023 | Quarterly Results |
| 09 11 2023 | Interim Dividend & Quarterly Results |
| 10 02 2024 | Interim Dividend |
| 09 11 2024 | Quarterly Results |
| 06 02 2025 | Quarterly Results |
| 26 05 2025 | Audited Results |
| 04 08 2025 | Interim Dividend & Quarterly Results |
| 05 11 2025 | Quarterly Results |
| 09 02 2026 | Quarterly Results |
| 06 04 2026 | Buy Back of Shares |
| 21 05 2026 | Audited Results |
News
Aurobindo Pharma’s arm’s Telangana facility classified as official action indicated
The USFDA had conducted inspection of the said unit from February 16 to February 27, 2026
Aurobindo Pharma reports marginal rise in Q4 consolidated net profit
Consolidated total income of the company increased by 5.32% at Rs 8,970.38 crore for Q4FY26
Aurobindo Pharma’s arm incorporates wholly owned subsidiary in France
The object of incorporation of this wholly owned subsidiary is to expand the manufacturing of generic formulations in France
Aurobindo Pharma’s arm gets CDSCO’s marketing authorisation for Bevqolva
The authorisation permits manufacture at CuraTeQ’s facility in Hyderabad and marketing of Bevqolva in 100 mg/4mL and 400 mg/16 mL vial presentations
Aurobindo Pharma gets EIR for Telangana unit
The USFDA has classified the said facility as Voluntary Action Indicated
Aurobindo Pharma’s arm gets Health Canada’s nod for Bevqolva bevacizumab biosimilar
Bevacizumab, a humanized monoclonal antibody, inhibits angiogenesis - the formation of new blood vessels - by blocking VEGF-A
Aurobindo gets nod for Dextromethorphan Polistirex Extended-Release Oral Suspension
The product will be manufactured at Unit-IV of APL Healthcare, a wholly owned subsidiary of the company, and will be launched in Q2FY27
Aurobindo Pharma gets USFDA’s final nod for Glycerol Phenylbutyrate Oral Liquid
The product will be manufactured by Unit-III of the company and will be launched immediately
Aurobindo Pharma’s arm signs additional product schedule with MSD
TheraNym will invest around $150 to $175 million for establishing said facility
Aurobindo Pharma gets USFDA’s final nod for Dapagliflozin tablets
These products will be manufactured at Unit-IV of APL Healthcare, a wholly owned subsidiary of the company
Aurobindo Pharma gets final nod for Dapagliflozin, Metformin Hydrochloride Extended-Release Tablets
These products will be manufactured at unit-IV of APL Healthcare, a wholly owned subsidiary of the Company and will be launched immediately
Aurobindo Pharma’s arm gets EIR for Telangana unit
The USFDA has classified the said facility as Voluntary Action Indicated and this inspection is now closed
Aurobindo Pharma’s arm gets OAI classification from USFDA for Rajasthan unit-II
At the end of the inspection, a ‘Form 483’ was issued with 09 observations
Aurobindo Pharma’s arm gets EIR for Unit-IV facility in Andhra Pradesh
The USFDA has classified the facility as ‘Voluntary Action Indicated’
Aurobindo Pharma’s arm launches Pomalidomide Capsules in US
Eugia Pharma Specialities was one of the First-to-File ANDA applicants for this product
USFDA completes inspection at Aurobindo Pharma’s arm’s Formulation facility in Telangana
The inspection concluded with 4 observations
Aurobindo Pharma’s arm gets USFDA’s nod to manufacture, market ‘Everolimus Tablets’
This approval has been received from Eugia Unit-I and is expected to be launched in Q1FY27
Aurobindo Pharma incorporates wholly owned subsidiary
The object of incorporation is to expand the contract manufacturing and other pharmaceutical manufacturing operations
Aurobindo Pharma reports 8% rise in Q3 consolidated net profit
The consolidated total income of the company increased by 8.58% at Rs 8,833.54 crore for Q3FY26
Aurobindo Pharma’s arm gets 11 observations from USFDA for Telangana Formulation facility
The inspection was conducted from January 27 to February 06, 2026
Aurobindo Pharma’s arm receives Notice of Compliance for ‘Dyrupeg’
CuraTeQ Biologics has obtained Notice of Compliance from Biologics and Radiopharmaceutical Drugs Directorate
Aurobindo’s arm approves acquisition of Khandelwal Lab’s non-oncology prescription formulations business
The Business has around 470 people strong field force and has more than 1600 stockists and other distribution related infrastructure
Aurobindo Pharma’s arm to terminate agreement with BioFactura Inc, USA
This decision is aligned with CuraTeQ’s strategic portfolio prioritisation
Aurobindo Pharma’s arm to acquire 20% additional ownership in Luoxin Aurovitas
The object of acquisition is to expand the manufacturing to economies of scale by adding 2 high Speed Lines and cater market demand
USFDA concludes inspection at unit-IV of Aurobindo Pharma’s arm
At the end of the current inspection, a ‘Form 483’ was issued with 05 observations which are procedural in nature
Aurobindo Pharma’s arm gets 3 observations from USFDA for Telangana API facility
The inspection was conducted from December 1 to December 12, 2025
Aurobindo Pharma reports marginal rise in Q2 consolidated net profit
The consolidated total income of the company increased by 5.98% at Rs 8,406.29 crore for Q2FY26
Aurobindo Pharma’s arm incorporates wholly owned subsidiary in South America
The object of incorporation of this wholly owned subsidiary is to expand the Pharmaceutical Products business in Chile
Aurobindo Pharma’s arm incorporates wholly owned subsidiary in Malta
The object of incorporation of this wholly owned step-down subsidiary is to expand the Pharmaceutical Products business in Malta
USFDA completes inspection at Aurobindo Pharma’s Unit-XII in Telangana
The USFDA has issued ‘Form 483’ with total of 8 observations for both (oral solids & injectable)
USFDA completes inspection at Aurobindo Pharma’s arm’s API manufacturing facility in Telangana
At the end of the current inspection, a ‘Form 483’ was issued with 5 observations which are procedural in nature and no data integrity issues were reported
Aurobindo Pharma’s arm obtains marketing authorization for Dazublys in UK
Earlier in July 2025, Dazublys has received the marketing authorisation in the European Union from the European Commission
Aurobindo Pharma’s arm to acquire 100% membership interest in Lannett Company LLC
The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities
Aurobindo Pharma to manufacture, supply long-acting HIV treatment cabotegravir across 133 countries
This is a significant and timely step towards increasing access to advanced long-acting treatment in LMICs
Aurobindo Pharma’s arm obtains marketing authorization for Dazublys
The company’s arm has obtained marketing authorization from the European Commission
Aurobindo Pharma’s arm restarts Penicillin-G manufacturing facility in AP
Lyfius Pharma has re-started the production at its Penicillin-G manufacturing facility, after receiving the consent to operate from APPCB
Aurobindo Pharma’s arm obtains marketing authorization from MHRA for Dyrupeg
Earlier in April 2025, Dyrupeg received marketing authorization in the European Union from the European Commission
Aurobindo Pharma’s arm incorporates wholly owned subsidiary in USA
The object of incorporation of this wholly owned subsidiary is to expand the Pharmaceutical Products business in USA
Aurobindo Pharma’s arm incorporates wholly owned subsidiary in Netherlands
The object of incorporation of this WOS is to expand the biopharma products business in Europe
Aurobindo Pharma’s arm obtains marketing authorisation from MHRA for biosimilar Zefylti
Earlier in February 2025, Zefylti has received the marketing authorisation in the European Union from the European Commission
Aurobindo Pharma’s arm gets USFDA’s nod to manufacture, market Dasatinib tablets
The product is expected to be launched in Q1FY26
Aurobindo Pharma gets USFDA’s nod to manufacture, market Rivaroxaban Tablets USP
The product will be launched in Q1FY26
USFDA concludes inspection at Raleigh plant of Aurobindo Pharma’s arm
At the conclusion, the USFDA issued a Form 483 with 11 observations
Aurobindo Pharma’s arm gets marketing authorization for Dyrupeg
Earlier in January 2025, the Committee for Medicinal Products of European Medicines Agency had adopted positive opinion recommending the approval of Dyrupeg
Aurobindo Pharma acquires 80% stake in Tergene Biotech
Tergene has become a direct subsidiary of the company
USFDA completes inspection at Andhra Pradesh facility of Aurobindo Pharma’s arm
The inspection concluded with 5 observations
Aurobindo Pharma to commence supplies to Europe from China facility from April
The company expects good traction coming out of the China plant over the next 2-3 years
Aurobindo Pharma’s arm gets marketing authorization for Zefylti
The company has received marketing authorization from The European Commission
Aurobindo Pharma reports 10% fall in Q3 consolidated net profit
Total consolidated income of the company increased by 8.27% at Rs 8135.81 crore for Q3FY25
Aurobindo Pharma’s step-down arm gets UK’s MHRA’s nod for Bevqolva
Bevqolva 25 mg/mL concentrate for infusion will be available in 4 mL (100 mg) and 16 mL (400 mg) single-use vials for infusion into veins
USFDA completes inspection at API manufacturing facility of Aurobindo Pharma’s arm
The inspection closed with 02 observations
Aurobindo Pharma’s arm recalling over 1 lakh bottles of Cinacalcet tablets in multiple strengths
The company initiated the Class II recall on November 7, 2024
Aurobindo Pharma’s arm gets USFDA’s approval for Pazopanib Tablets
The product is expected to be launched in Q4FY25
Aurobindo Pharma’s arm enters into agreement with global pharma major
Both the parties will co-exclusively commercialize the product
Aurobindo Pharma’s arm gets GMP certificate of compliance for Hyderabad facility
The GMP inspection was conducted by EMA representatives from April 8 to April 12, 2024
Aurobindo Pharma’s Q2FY25 consolidated net profit rises by 9%
Consolidated total income of the company increased by 7.10% at Rs 7,932.07 crore for Q2FY25
Aurobindo Pharma completes acquisition of balance 49% stake of GLS Pharma
The aforementioned acquisition has been completed on October 25, 2024
Aurobindo Pharma’s arm to sell 50% shares in Novagen
After the disposal of 50% shares held by Aurogen, Aurogen will cease to be the joint venture partner of Novagen
Aurobindo Pharma gets USFDA’s final approval for Cephalexin Tablets
The product is expected to be launched in Q3FY25
USFDA completes inspection at API manufacturing facility of Aurobindo Pharma’s arm
The USFDA had conducted an inspection from September 23, 2024 to September 27, 2024 at this facility
Aurobindo Pharma inks pact to acquire balance 49% stake in GLS Pharma
The completion of the acquisition is estimated before December 31, 2024
Aurobindo Pharma’s arm gets EIR for Andhra Pradesh facility
The USFDA had conducted an inspection from March 28, 2024 to April 05, 2024 at this facility
USFDA concludes inspection at Andhra Pradesh facility of Aurobindo Pharma’s arm
The inspection closed with 3 observations
Aurobindo Pharma gets final nod to manufacture, market Mometasone Furoate Monohydrate Nasal Spray
The approved product has an estimated market size of $44.5 million for the twelve months ending January 2024
Aurobindo Pharma’s arm restarts distribution of aseptic products manufactured at Unit III
The company also expects to start commercial production from the aseptic lines of the said facility in a phased manner beginning next week
Aurobindo Pharma gets final nod to manufacture, market Fingolimod Capsules, 0.5 mg
The product will be launched in March 2024
USFDA concludes inspection at injectable facility of Aurobindo Pharma’s arm
The inspection closed with 7 observations
USFDA concludes inspection at synthetic peptide API facility of Aurobindo Pharma’s arm
The inspection was concluded with zero observations
Aurobindo Pharma gets USFDA’s final nod for Deflazacort Tablets
The product will be launched in February 2024
Aurobindo Pharma reports 91% rise in Q3 consolidated net profit
Consolidated total income of the company increased by 15.61% at Rs 7514.30 crore for Q3FY24
Aurobindo Pharma gets Establishment Inspection Report for Telangana facility
USFDA had conducted an inspection at the Unit VI-B, a Formulation manufacturing facility of the Company
Aurobindo Pharma gets EIR for Andhra Pradesh manufacturing facility
The said facility has been classified as Voluntary Action Indicated
Aurobindo Pharma’s arm gets USFDA’s final nod for Budesonide Inhalation Suspension
The product is expected to be launched in FY25
Aurobindo Pharma gets USFDA’s final nod for Darunavir Tablets
The product will be launched on November 29, 2023
Aurobindo Pharma incorporates wholly owned subsidiary
Auro Trading is incorporated for carrying on trading in generic formulations business
USFDA conducts inspection at units of Aurobindo Pharma’s arm
The inspection closed with zero observations
Aurobindo Pharma reports 83% rise in Q2 consolidated net profit
Total consolidated income of the company increased by 27.77% at Rs 7,406.40 crore for Q2FY24
Aurobindo Pharma gets nod to acquire stake in Theranym Biologics
The Board of Directors of the Company at its meeting held November 9, 2023, has approved the same
Aurobindo Pharma’s arm gets USFDA’s final nod for Testosterone Cypionate Injection
The product is expected to be launched in November 2023
Aurobindo Pharma’s step-down arm inaugurates green-field manufacturing Unit at Vishakhapatnam
This Unit will manufacture general injectables and expected to supply globally in phases
Aurobindo Pharma’s unit recalling 9,890 bottles of Rasagiline Tablets in US
New Jersey-based Aurobindo Pharma USA Inc is recalling the affected lot due to ‘Failed dissolution specifications’
US FDA completes inspection at Aurobindo Pharma’s Telangana manufacturing facility
US FDA has conducted inspection from September 22 to September 29, 2023
Aurobindo Pharma’s arm enters into Licence agreement with Hilleman Laboratories Singapore
Hilleman will also be paid royalties upon commercialization of the vaccine candidate
USFDA completes inspection at formulation manufacturing facility of Aurobindo Pharma’s arm
At the end of the inspection, a ‘Form 483’ was issued with 1 observation which is procedural in nature
Aurobindo Pharma gets EIR for Telangana manufacturing facility
The said facility classified as Voluntary Action Indicated
Aurobindo Pharma’s arm recalls bottles of Rufinamide Tablets
Aurobindo Pharma USA Inc is also recalling 48 bottles of the same medication in different strengths (USP 400 mg) for similar reasons
Aurobindo Pharma to launch HIV triple combination product for children living with HIV
Aurobindo’s product is already filed with the DCGI and is expected to be approved soon
Aurobindo Pharma reports over 9% rise in Q1 consolidated net profit
Total consolidated income of the company increased by 11% at Rs 6,966.85 crore for Q1FY24
Aurobindo Pharma’s arm gets nod to manufacture, market Vancomycin Hydrochloride for injection
The approved product has an estimated market size of around $34.4 million for the twelve months ending May 2023
USFDA completes PAI at Aurobindo Pharma’s Unit VII in Telangana
The inspection closed with zero observations and a classification of No Action Indicated
Aurobindo Pharma gets nod to manufacture, market Saxagliptin Tablets
Aurobindo is eligible for 180 days of shared generic drug exclusivity for Saxagliptin Tablets, 2.5 mg and 5 mg
USFDA completes inspection at formulation manufacturing facility of Aurobindo Pharma’s arm
The inspection closed with zero observations and a classification of No Action Indicated
Aurobindo Pharma’s arm gets USFDA’s final approval for Plerixafor Injection
The product is being launched in July FY24
USFDA inspects Aurobindo Pharma’s Formulation manufacturing facility in Telangana
At the end of the inspection, the company has been issued a ‘Form 483’ with 3 observations
Aurobindo Pharma’s arm gets USFDA’s approval for Sevelamer Hydrochloride Tablets
The approved product has an estimated market size of around $37 million for the twelve months ending May 2023, according to IQVIA
Aurobindo Pharma’s arm enters into exclusive license agreement with BioFactura
CuraTeQ intends to file this product in India and Emerging Markets as early as in 2024 and the regulated markets filing is expected to begin in 2026
Aurobindo Pharma’s group entity inks pact with Viatris
The arrangement also contemplates participation in the supply system in relation to certain marketing and manufacturing related authorisations
Aurobindo Pharma’s arm inks voluntary license with Medicines Patent Pool
The product will be produced at the Eugia Pharma Specialities Unit-I, Medchal, Malkajgiri District, Telangana, India
Aurobindo Pharma reports 12% fall in Q4 consolidated net profit
Total consolidated income of the company increased by 12.80% at Rs 6,607.87 crore for Q4FY23
Aurobindo Pharma gets nod to sell stake in Auro Vaccines
The Board of Directors of Aurobindo Pharma at its meeting held on May 27, 2023, has approved the same
Aurobindo Pharma’s arm receives USFDA’s final approval for Carboprost Tromethamine Injection
The product is expected to be launched in June 2023
USFDA completes inspection at Unit XIV of Aurobindo Pharma
The company has been issued a ’Form 483’ with four observations
Aurobindo Pharma inks voluntary license with Medicines Patent Pool
The company has signed voluntary sub-licensing for developing and marketing Cabotegravir Tablets & Long Acting Injectables
Aurobindo Pharma’s arm receives USFDA’s final approval for Lenalidomide Capsules
The product is expected to be launched in October 2023
Aurobindo Pharma gets nod to transfer of API Non-Antibiotic Division to Auro Pharma India
Transfer of API Non-Antibiotic Division will be done for a lumpsum consideration of Rs 3,303.17 crore
Aurobindo Pharma’s arm receives USFDA’s approval for Diclofenac Sodium Topical Solution USP
The product is expected to be launched in Q1FY24
Aurobindo Pharma’s arm gets 2 observations from USFDA
The observations are procedural in nature
Aurobindo Pharma’s arm gets final approval from USFDA for Azacitidine Injection
The product is expected to be launched by this month
Aurobindo Pharma’s JV receives SEC recommendation for pneumococcal 15 valent vaccine
Aurobindo Pharma holds 80% stake in the Joint Venture company, Tergene Biotech
Aurobindo Pharma’s arm enters into license agreement with Evive Biotech
The Biologics License Application of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia
Aurobindo Pharma aiming to complete Pen G plant in Andhra Pradesh by March 2024
The production capacity of the plant will be around 15,000 tonnes annually
Aurobindo Pharma’s arm receives USFDA approval for Amphotericin B Liposome for Injection.
The approved product has an estimated market size of around $145 million
Aurobindo Pharma gets EIR from USFDA for manufacturing facility in Andhra Pradesh
The company’s Unit XI at Pydibhimavaram is an API non-antibiotic manufacturing facility
Aurobindo Pharma reports 41% fall in Q2 consolidated net profit
Total consolidated income of the company decreased by 4.01% at Rs 5796.56 crore for Q2FY23
Aurobindo Pharma’s unit recalling 88,080 vials of Tranexamic acid injection
AuroMedics commenced the Class III recall in the US on September 26
Aurobindo Pharma’s arm receives EIR for Raleigh plant
With this, the USFDA pre-approval inspection and GMP inspection are concluded
Aurobindo Pharma’s arm gets nod to expand mammalian cell culture manufacturing facility
The capital expenditure for ramping up capacities is estimated to be around Rs 300 crore
USFDA completes inspection at Aurobindo Pharma’s Raleigh unit with 1 observation
The observation is procedural in nature and there are no data integrity issues
Aurobindo Pharma’s arm gets nod to manufacture, market Medroxyprogesterone Acetate Injectable Suspension
The approved product has an estimated market size of around $ 62 million for the twelve months ending June 2022
Aurobindo Pharma acquires 51% stake in GLS Pharma
Post-acquisition GLS Pharma has become the subsidiary of the company
Aurobindo Pharma’s arm receives USFDA’s approval for Vasopressin Injection
The product is being launched immediately
Aurobindo Pharma reports 32% fall in Q1 consolidated net profit
Total consolidated income of the company increased by 8% at Rs 6,276.54 crore for Q1FY23
USFDA completes inspection at Unit VII of Aurobindo Pharma
The Company’s Unit VII, an oral manufacturing facility situated at Jedcherla, Hyderabad, received an Establishment Inspection Report
Aurobindo Pharma gets 3 observations from USFDA for Andhra Pradesh unit
The company will respond to the USFDA within the stipulated timeline and work closely with the regulator to address the observations at the earliest
Aurobindo Pharma’s arm gets USFDA nod for Triamcinolone Acetonide injectable suspension
The product is being launched this month
Aurobindo Pharma acquires business and certain assets of Veritaz Healthcare
Earlier, the company had received approval of the Board of Directors of the Company for the acquisition of the same
Aurobindo Pharma gets warning letter from SEBI
The SEBI warning letter observes that the Company had disclosed very limited and restricted information
Aurobindo Pharma gets nod to acquire 51% stake in GLS Pharma
The Board of Directors of the Company at its meeting held on June 17, 2022, has approved the same
Aurobindo Pharma’s arm gets USFDA approval for Leuprolide Acetate injection
The product is being launched this month